Identifying Pathways Related to Bladder Cancer
Author Information
Author(s): Malene Herbsleb, Ole F. Christensen, Thomas Thykjaer, Carsten Wiuf, Michael Borre, Torben F. Ørntoft, Lars Dyrskjøt
Primary Institution: Aarhus University Hospital Skejby
Hypothesis
Can pathway analysis predict the presence of carcinoma in situ (CIS) in bladder cancer patients?
Conclusion
Pathway analysis can effectively classify bladder tumors based on the presence of concomitant CIS.
Supporting Evidence
- TF expression levels in three pathways could predict the presence of concomitant CIS.
- A cluster analysis separated patients with and without CIS based on gene expression.
- Validation in an independent test set confirmed the ability to predict CIS status.
Takeaway
Researchers found that certain gene pathways can help tell if bladder cancer is at an early stage or more advanced.
Methodology
The study used a pathway-based classifier approach and Leave-One-Out Cross Validation to predict CIS presence based on transcription factor expression.
Potential Biases
Potential biases may arise from the selection of samples and the methods used for gene expression analysis.
Limitations
The sample size was relatively small, which may limit the generalizability of the findings.
Participant Demographics
Patients included 15 with non-CIS tumors and 13 with concomitant CIS, all with no history of muscle-invasive tumors.
Statistical Information
P-Value
0.0004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website